Skip to main content
Home

Cardiology Associations

This page includes news coverage of cardiology societies and associations. Follow these links for specific cardiology society news pages: American College of Cardiology (ACC), American Heart Association (AHA), American Society of Echocardiography (ASE),  American Society Nuclear Cardiology (ASNC), European Society of Cardiology (ESC), Heart Rhythm Society (HRS), Society for Cardiovascular Angiography Interventions (SCAI), Society of Cardiovascular Computed Tomography (SCCT), Transcatheter Cardiovascular Therapeutics (TCT), and Vascular Interventional Advances (VIVA). 

RSS icon

  • Thumbnail

    Chest pain drug lowers risk of kidney injury after PCI

    Treating certain high-risk PCI patients with nicorandil before and after treatment can significantly reduce their risk of contrast-related injuries.

  •  Derek Pineda, FNP, CCRN, RCIS, FACC, with Mount Sinai Fuster Heart Hospital, explains the use of a digital app platform for STEMI team coordination that helped his health system improve STEMI outcomes.

    New digital platform gets clinicians on the same page when treating heart attacks

    One of the platform's biggest benefits is the rich clinical information it provides to all members of the care team.

  • heart doctor cardiologist

    Sex-specific outcomes after TAVR and SAVR: Key takeaways from a new meta-analysis

    TAVR was associated with early benefits for women. After five years, however, outcomes were comparable across the board.

  • Hundreds of cardiologists incorrectly added to new mandatory payment model

    When CMS shared a list of cardiologists being targeted with a brand new payment model, the American College of Cardiology identified a long list of apparent mistakes.

  • Medaxiom CEO Jerry Blackwell, MD, explains the role of private equity in cardiology and that it is a small player in cardiology practice ownership.

    Private equity unlikely to dominate cardiology despite hype

    Medaxiom CEO Jerry Blackwell, MD, MBA, FACC, discusses investor's interest in buying cardiology practices, noting that PE ownership remains relatively low.

Thumbnail

Gene-editing therapy lowers cholesterol in high-risk heart patients—one dose could potentially last decades

While the therapy has been successfully tested on animals in the past, this study represents the first time it has been used on humans.

Prosthesis-patient mismatch (PPM) after TAVR

Cardiologists may want to rethink how they track prosthesis-patient mismatch after TAVR

Researchers evaluated two techniques for predicting PPM after TAVR, comparing them to how cardiologists typically check for PPM in day-to-day practice. 

cannabis use disorder marijuana joint weed smoking

Daily marijuana use increases heart failure risk by 34%

“Marijuana use isn’t without its health concerns, and our study provides more data linking its use to cardiovascular conditions," one researcher said. 

artificial intelligence AI heart cardiology

ChatGPT struggles with echocardiography, but still shows potential to help cardiology trainees

ChatGPT may not be quite ready to help prepare trainees for their next echocardiography exam—but it does show promise. 

Jamie Bourque, MD, discusses fluorodeoxyglucose (FDG) and its growing use cases in cardiac PET imaging He discussed the radiotracer in sessions at ASNC 2023. #ASNC #ASNC23 #ASNC2023

The expanding scope of FDG-PET in nuclear cardiac imaging

Jamie Bourque, MD, spoke to Cardiovascular Business about the growing number of ways FDG-PET scans are being used in cardiology. This includes evaluating inflammation, tracking EP device infections and much more. 

Thumbnail

TAVR linked to favorable outcomes for asymptomatic and minimally symptomatic patients—but is it necessary?

While TAVR is safe for minimally symptomatic patients, questions remain about whether or not it is actually needed. A new analysis in JACC: Cardiovascular Interventions examines this topic in detail.

A closer look at how weight loss drug semaglutide improves the cardiovascular health of obese patients without diabetes

Novo Nordisk shared initial results from the SELECT trial back in August, but now the full analysis—which includes data from more than 17,000 patients—has been published in The New England Journal of Medicine. 

Ramon Varcoe explains the LIFE-BTK trial for the Abbott Esprit fully bioresobable scaffold at TCT23.

Fully bioresorbable stents boost care for CLI patients in LIFE-BTK trial

Ramon Varcoe, MBBS, co-principal investigator for the LIFE-BTK trial, discussed the results with Cardiovascular Business at TCT 2023. "I can't wait to start using these in my patients. It's going to make a huge difference."

Pagination

    • First page « First
    • Previous page ‹ Previous
    • Page …104
    • Page 105
    • Page 106
    • Page 107
    • Current page 108
    • Page 109
    • Page 110
    • Page 111
    • Page 112 …
    • Next page Next ›
    • Last page Last »
Displaying 857 - 864 of 1559
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme